Sofosbuvir patent dispute- Delhi High Court update

A writ petition was filed before the Delhi High Court by I-MAK and DNP+, challenging the grant of patent to costly Hepatitis-C drug, Sofosbuvir. The first hearing for the case was expected take place on 13th September. However, the hearing has been adjourned. Patent Controller and Union of India asked for postponement of the case as they needed more time to submit their response to the petition.  The patent was granted to Gilead for this drug in May 2016.

The judge has given a week’s time to make the submission. However, next date given for hearing is now for 22nd November.

Read I-MAK/DNP+ press release issued in July 

http://www.i-mak.org/news-releases/

MSF Press release issued on grant of patent 

http://www.msfaccess.org/about-us/media-room/press-releases/after-initially-rejecting-patent-indian-patent-office-grants-gi

This entry was posted in Hepatitis C, Patent, Sofosbuvir, Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s